View Future GrowthChimeric Therapeutics 過去の業績過去 基準チェック /06Chimeric Therapeuticsの収益は年間平均-9.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間36.2% 79.2%割合で 増加しています。主要情報-9.23%収益成長率37.82%EPS成長率Biotechs 業界の成長17.04%収益成長率79.17%株主資本利益率-507.27%ネット・マージン-168.01%前回の決算情報30 Jun 2024最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australiaお知らせ • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct Listingお知らせ • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offeringお知らせ • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offeringお知らせ • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct Listingお知らせ • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australiaお知らせ • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights Offeringお知らせ • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.お知らせ • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.お知らせ • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.お知らせ • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.お知らせ • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".お知らせ • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.お知らせ • Jan 24Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 TrialChimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.お知らせ • Jan 20Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib TrialChimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.収支内訳Chimeric Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CHMM.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費30 Jun 247-13101131 Mar 2410-12111131 Dec 2312-12121230 Sep 238-19141330 Jun 235-26151431 Mar 235-22141231 Dec 226-1813930 Sep 224-1712830 Jun 223-1611631 Mar 221-1913631 Dec 210-2114630 Sep 210-1813530 Jun 210-15114質の高い収益: CHMM.Fは現在利益が出ていません。利益率の向上: CHMM.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CHMM.Fは利益が出ておらず、過去 5 年間で損失は年間9.2%の割合で増加しています。成長の加速: CHMM.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CHMM.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: CHMM.Fは現在利益が出ていないため、自己資本利益率 ( -507.27% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/04 02:25終値2024/09/06 00:00収益2024/06/30年間収益2024/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chimeric Therapeutics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Hunter DiamondDiamond Equity Research LLCMaxim JacobsEdison Investment Researchnull nullLodge Partners Pty Ltd.
お知らせ • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia
お知らせ • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct Listing
お知らせ • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offering
お知らせ • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offering
お知らせ • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia
お知らせ • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights Offering
お知らせ • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.
お知らせ • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.
お知らせ • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.
お知らせ • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.
お知らせ • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".
お知らせ • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.
お知らせ • Jan 24Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 TrialChimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.
お知らせ • Jan 20Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib TrialChimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.